TIAA CREF Investment Management’s CytomX Therapeutics CTMX Stock Holding History

TIAA CREF Investment Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$1.64M	Sell	152,943 -12,359	-7%	-$183K	﹤0.01%	2095
2018 Q4	$2.5M	Sell	165,302 -2,374	-1%	-$35.2K	﹤0.01%	1825
2018 Q3	$3.1M	Sell	167,676 -73,252	-30%	-$1.67M	﹤0.01%	1897
2018 Q2	$5.51M	Buy	240,928 +31,127	+15%	+$795K	﹤0.01%	1529
2018 Q1	$5.97M	Sell	209,801 -2,246	-1%	-$64.1K	﹤0.01%	1446
2017 Q4	$4.48M	Sell	212,047 -25,652	-11%	-$532K	﹤0.01%	1675
2017 Q3	$4.32M	Buy	237,699 +68,147	+40%	+$1.06M	﹤0.01%	1717
2017 Q2	$2.63M	Buy	169,552 +109,791	+184%	+$1.66M	﹤0.01%	2019
2017 Q1	$1.03M	Sell	59,761 -6,141	-9%	-$80.8K	﹤0.01%	2489
2016 Q4	$724K	Sell	65,902 -186	-0.3%	-$2.25K	﹤0.01%	2686
2016 Q3	$1.04K	Sell	66,088 -280	-0.4%	-$3.39K	﹤0.01%	2524
2016 Q2	$678K	Buy	66,368 +49,158	+286%	+$561K	﹤0.01%	2725
2016 Q1	$222K	Hold	17,210	–	–	﹤0.01%	2964
2015 Q4	$359K	Buy	+17,210	New	+$272K	﹤0.01%	2981

Other funds holding CTMX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TIAA CREF Investment Management's CTMX Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its CytomX Therapeutics (CTMX) stake by 7.5% in Q1 2019, selling an estimated $183K and leaving 152,943 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #2095.

TIAA CREF Investment Management first reported a position in CTMX in Q4 2015 and has held it in 14 quarters since. The position peaked at $5.97M in Q1 2018. 113 funds tracked by Wall St. Rank hold CTMX as of Q1 2019.

TIAA CREF Investment Management held 152,943 shares of CytomX Therapeutics worth $1.64M as of Q1 2019.
TIAA CREF Investment Management sold 12,359 CytomX Therapeutics shares in Q1 2019, an estimated $183K.
CytomX Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2095 holding.
TIAA CREF Investment Management first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 14 quarters since.
TIAA CREF Investment Management's CytomX Therapeutics position peaked at $5.97M in Q1 2018.
113 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.